Cover Image
市場調查報告書

肝纖維化:開發中產品分析

Liver Fibrosis - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 213097
出版日期 內容資訊 英文 199 Pages
訂單完成後即時交付
價格
Back to Top
肝纖維化:開發中產品分析 Liver Fibrosis - Pipeline Review, H2 2016
出版日期: 2016年09月14日 內容資訊: 英文 199 Pages
簡介

肝纖維化是由於肝臟反應慢性肝臟疾病,開始形成疤痕的過程,是由於肝臟反覆受到損傷所造成的。常見有急性發炎、衰弱、黃膽等症狀。

本報告提供肝纖維化的治療藥開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,再加上主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

簡介

  • 調查範圍

肝纖維化概要

治療藥的開發

  • 開發中產品的概要
  • 開發中產品比較分析

肝纖維化:企業開發中的治療藥

肝纖維化:大學/機關研究中的治療藥

肝纖維化:開發中產品概況

  • 臨床階段的產品
  • 初期階段的產品

肝纖維化:企業開發中的產品

肝纖維化:大學/機關研究中的產品

肝纖維化的治療藥的開發企業

  • Advinus Therapeutics Ltd.
  • AiCuris GmbH & Co. KG
  • Akarna Therapeutics Ltd.
  • Angion Biomedica Corp.
  • Asubio Pharma Co., Ltd.
  • Bioneer Corporation
  • BiOrion Technologies B.V.
  • Bird Rock Bio, Inc.
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • Dicerna Pharmaceuticals, Inc.
  • Digna Biotech, S.L.
  • Dr. Falk Pharma GmbH
  • Dynavax Technologies Corporation
  • Evotec AG
  • FibroGen, Inc.
  • Galectin Therapeutics, Inc.
  • Genfit SA
  • Gilead Sciences, Inc.
  • GNI Group Ltd.
  • HEC Pharm Co., Ltd.
  • Immuron Limited
  • Intercept Pharmaceuticals, Inc.
  • INVENT Pharmaceuticals, Inc.
  • Isarna Therapeutics GmbH
  • KineMed, Inc.
  • LG Life Science LTD.
  • Nitto Denko Corporation
  • Pfizer Inc.
  • Pharmaxis Limited
  • Promedior, Inc.
  • Promethera Biosciences S.A.
  • ProMetic Life Sciences Inc.
  • RXi Pharmaceuticals Corporation
  • SciFluor Life Sciences, LLC
  • TCM Biotech International Corp
  • Vascular Biogenics Ltd.
  • Virobay Inc.
  • XTuit Pharmaceuticals, Inc.

肝纖維化:治療藥的評估

  • 單劑產品
  • 組合產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

肝纖維化:最近的開發平台趨勢

肝纖維化:暫停中的計劃

肝纖維化:開發中止的產品

肝纖維化:產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8453IDB

Summary

Global Markets Direct's, 'Liver Fibrosis - Pipeline Review, H2 2016', provides an overview of the Liver Fibrosis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Liver Fibrosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Liver Fibrosis and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Liver Fibrosis
  • The report reviews pipeline therapeutics for Liver Fibrosis by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Liver Fibrosis therapeutics and enlists all their major and minor projects
  • The report assesses Liver Fibrosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Liver Fibrosis

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Liver Fibrosis
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Liver Fibrosis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Liver Fibrosis Overview
  • Therapeutics Development
    • Pipeline Products for Liver Fibrosis - Overview
    • Pipeline Products for Liver Fibrosis - Comparative Analysis
  • Liver Fibrosis - Therapeutics under Development by Companies
  • Liver Fibrosis - Therapeutics under Investigation by Universities/Institutes
  • Liver Fibrosis - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
  • Liver Fibrosis - Products under Development by Companies
  • Liver Fibrosis - Products under Investigation by Universities/Institutes
  • Liver Fibrosis - Companies Involved in Therapeutics Development
    • Advinus Therapeutics Ltd
    • Akarna Therapeutics Ltd.
    • Angion Biomedica Corp.
    • Asubio Pharma Co., Ltd.
    • aTyr Pharma, Inc.
    • Beijing Kawin Technology Share-Holding Co., Ltd.
    • BioLineRx, Ltd.
    • Bioneer Corporation
    • BiOrion Technologies B.V.
    • Bird Rock Bio, Inc.
    • Bristol-Myers Squibb Company
    • Cellmid Limited
    • ContraVir Pharmaceuticals, Inc.
    • Dicerna Pharmaceuticals, Inc.
    • Digna Biotech, S.L.
    • Dr. Falk Pharma GmbH
    • Dynavax Technologies Corporation
    • Evotec AG
    • Galectin Therapeutics, Inc.
    • Genfit SA
    • Gilead Sciences, Inc.
    • GNI Group Ltd.
    • HEC Pharm Co., Ltd.
    • Immuron Limited
    • Intercept Pharmaceuticals, Inc.
    • INVENT Pharmaceuticals, Inc.
    • Isarna Therapeutics GmbH
    • KineMed, Inc.
    • LG Life Science LTD.
    • Nitto Denko Corporation
    • Pfizer Inc.
    • Pharmaxis Limited
    • Promedior, Inc.
    • Promethera Biosciences S.A.
    • ProMetic Life Sciences Inc.
    • Ribomic Inc.
    • RXi Pharmaceuticals Corporation
    • Silence Therapeutics Plc
    • TCM Biotech International Corp
    • Vascular Biogenics Ltd.
    • Virobay Inc.
    • XTuit Pharmaceuticals, Inc.
  • Liver Fibrosis - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • ANG-3070 - Drug Profile
    • ANG-3281 - Drug Profile
    • Antisense RNAi Oligonucleotide for Liver Disease - Drug Profile
    • Antisense RNAi Oligonucleotide for Liver Diseases - Drug Profile
    • Antisense RNAi Oligonucleotide for Liver Fibrosis - Drug Profile
    • Antisense RNAi Oligonucleotide for Liver Fibrosis - Drug Profile
    • Antisense RNAi Oligonucleotide for Liver Fibrosis - Drug Profile
    • Antisense RNAi Oligonucleotide to Inhibit Beta Catenin for Liver Fibrosis - Drug Profile
    • Antisense RNAi Oligonucleotide to Inhibit HMGB1 for Liver Fibrosis - Drug Profile
    • ASB-14780 - Drug Profile
    • BL-1210 - Drug Profile
    • BMS-986171 - Drug Profile
    • BOT-162 - Drug Profile
    • BOT-191 - Drug Profile
    • CAB-102 - Drug Profile
    • CPI-43132 - Drug Profile
    • CT-140 - Drug Profile
    • DB-036 - Drug Profile
    • Drug to Inhibit Galectin-3 for Liver Fibrosis, Respiratory Disorder and Kidney Fibrosis - Drug Profile
    • Drugs for Tissue Fibrosis - Drug Profile
    • DV-1079 - Drug Profile
    • F-351 - Drug Profile
    • Gene Therapy for Liver Fibrosis - Drug Profile
    • GMCT-01 - Drug Profile
    • GRMD-02 - Drug Profile
    • GS-444217 - Drug Profile
    • HEC-585 - Drug Profile
    • HepaStem - Drug Profile
    • IMM-124E - Drug Profile
    • INT-767 - Drug Profile
    • INV-240 - Drug Profile
    • ISTH-0047 - Drug Profile
    • KW-0 - Drug Profile
    • KW-012 - Drug Profile
    • LC-280126 - Drug Profile
    • melittin - Drug Profile
    • Monoclonal Antibodies to Antagonize TGF-Beta Receptor Type-1 for HCV associated Liver Fibrosis - Drug Profile
    • MOR-8457 - Drug Profile
    • MRI-1867 - Drug Profile
    • ND-L02s0201 - Drug Profile
    • norursodeoxycholic acid - Drug Profile
    • noscapine - Drug Profile
    • PBI-4050 - Drug Profile
    • PRM-151 - Drug Profile
    • Proteins for Liver Fibrosis - Drug Profile
    • PXS-4820 - Drug Profile
    • PXS-5033A - Drug Profile
    • RBM-006 - Drug Profile
    • Recombinant MMP-9 Replacement for Liver Fibrosis, Pulmonary Fibrosis, Dupuytren Contracture, Peyronies Disease and Transplantation - Drug Profile
    • RXI-209 - Drug Profile
    • RYI-018 - Drug Profile
    • selonsertib - Drug Profile
    • selonsertib + simtuzumab - Drug Profile
    • Small Molecule for Liver Fibrosis - Drug Profile
    • Small Molecule for Liver Fibrosis - Drug Profile
    • Small Molecule to Agonize FXR for NASH and Liver Fibrosis - Drug Profile
    • Small Molecule to Antagonize AlphaVBetaI for Fibrosis - Drug Profile
    • Small Molecule to Antagonize GPR91 for Retinal Angiogenesis and Liver Fibrosis - Drug Profile
    • Small Molecules for Hepatic Fibrosis - Drug Profile
    • Small Molecules for Liver Fibrosis and Idiopathic Pulmonary Fibrosis - Drug Profile
    • Stem Cell Therapy for Fibrosis and Non-Alcoholic Steatohepatitis - Drug Profile
    • Stem Cell Therapy for Liver Fibrosis and Liver Cirrhosis - Drug Profile
    • TCM-808FB - Drug Profile
    • TGFTX-4 - Drug Profile
    • VB-201 - Drug Profile
    • VB-703 - Drug Profile
    • VBY-376 - Drug Profile
    • VBY-825 - Drug Profile
  • Liver Fibrosis - Dormant Projects
  • Liver Fibrosis - Discontinued Products
  • Liver Fibrosis - Product Development Milestones
    • Featured News & Press Releases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Liver Fibrosis, H2 2016
  • Number of Products under Development for Liver Fibrosis - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Development by Companies, H2 2016 (Contd..1)
  • Number of Products under Development by Companies, H2 2016 (Contd..2)
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Development by Companies, H2 2016 (Contd..2)
  • Products under Development by Companies, H2 2016 (Contd..3)
  • Products under Investigation by Universities/Institutes, H2 2016
  • Liver Fibrosis - Pipeline by Advinus Therapeutics Ltd, H2 2016
  • Liver Fibrosis - Pipeline by Akarna Therapeutics Ltd., H2 2016
  • Liver Fibrosis - Pipeline by Angion Biomedica Corp., H2 2016
  • Liver Fibrosis - Pipeline by Asubio Pharma Co., Ltd., H2 2016
  • Liver Fibrosis - Pipeline by aTyr Pharma, Inc., H2 2016
  • Liver Fibrosis - Pipeline by Beijing Kawin Technology Share-Holding Co., Ltd., H2 2016
  • Liver Fibrosis - Pipeline by BioLineRx, Ltd., H2 2016
  • Liver Fibrosis - Pipeline by Bioneer Corporation, H2 2016
  • Liver Fibrosis - Pipeline by BiOrion Technologies B.V., H2 2016
  • Liver Fibrosis - Pipeline by Bird Rock Bio, Inc., H2 2016
  • Liver Fibrosis - Pipeline by Bristol-Myers Squibb Company, H2 2016
  • Liver Fibrosis - Pipeline by Cellmid Limited, H2 2016
  • Liver Fibrosis - Pipeline by ContraVir Pharmaceuticals, Inc., H2 2016
  • Liver Fibrosis - Pipeline by Dicerna Pharmaceuticals, Inc., H2 2016
  • Liver Fibrosis - Pipeline by Digna Biotech, S.L., H2 2016
  • Liver Fibrosis - Pipeline by Dr. Falk Pharma GmbH, H2 2016
  • Liver Fibrosis - Pipeline by Dynavax Technologies Corporation, H2 2016
  • Liver Fibrosis - Pipeline by Evotec AG, H2 2016
  • Liver Fibrosis - Pipeline by Galectin Therapeutics, Inc., H2 2016
  • Liver Fibrosis - Pipeline by Genfit SA, H2 2016
  • Liver Fibrosis - Pipeline by Gilead Sciences, Inc., H2 2016
  • Liver Fibrosis - Pipeline by GNI Group Ltd., H2 2016
  • Liver Fibrosis - Pipeline by HEC Pharm Co., Ltd., H2 2016
  • Liver Fibrosis - Pipeline by Immuron Limited, H2 2016
  • Liver Fibrosis - Pipeline by Intercept Pharmaceuticals, Inc., H2 2016
  • Liver Fibrosis - Pipeline by INVENT Pharmaceuticals, Inc., H2 2016
  • Liver Fibrosis - Pipeline by Isarna Therapeutics GmbH, H2 2016
  • Liver Fibrosis - Pipeline by KineMed, Inc., H2 2016
  • Liver Fibrosis - Pipeline by LG Life Science LTD., H2 2016
  • Liver Fibrosis - Pipeline by Nitto Denko Corporation, H2 2016
  • Liver Fibrosis - Pipeline by Pfizer Inc., H2 2016
  • Liver Fibrosis - Pipeline by Pharmaxis Limited, H2 2016
  • Liver Fibrosis - Pipeline by Promedior, Inc., H2 2016
  • Liver Fibrosis - Pipeline by Promethera Biosciences S.A., H2 2016
  • Liver Fibrosis - Pipeline by ProMetic Life Sciences Inc., H2 2016
  • Liver Fibrosis - Pipeline by Ribomic Inc., H2 2016
  • Liver Fibrosis - Pipeline by RXi Pharmaceuticals Corporation, H2 2016
  • Liver Fibrosis - Pipeline by Silence Therapeutics Plc, H2 2016
  • Liver Fibrosis - Pipeline by TCM Biotech International Corp, H2 2016
  • Liver Fibrosis - Pipeline by Vascular Biogenics Ltd., H2 2016
  • Liver Fibrosis - Pipeline by Virobay Inc., H2 2016
  • Liver Fibrosis - Pipeline by XTuit Pharmaceuticals, Inc., H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Liver Fibrosis - Dormant Projects, H2 2016
  • Liver Fibrosis - Dormant Projects (Contd..1), H2 2016
  • Liver Fibrosis - Dormant Projects (Contd..2), H2 2016
  • Liver Fibrosis - Dormant Projects (Contd..3), H2 2016
  • Liver Fibrosis - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Liver Fibrosis, H2 2016
  • Number of Products under Development for Liver Fibrosis - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Top 10 Molecule Types, H2 2016
  • Number of Products by Stage and Top 10 Molecule Types, H2 2016
Back to Top